The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa

Hessel van der Zee; J de Boer; Errol Prens; GBE Jemec

doi:10.1159/000228337

The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa

Hessel van der Zee, J de Boer, Errol Prens, GBE Jemec

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

203 Citations (Scopus)

Abstract

Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established. Copyright (C) 2009 S. Karger AG, Basel

Original language	Undefined/Unknown
Pages (from-to)	143-147
Number of pages	5
Journal	Dermatology
Volume	219
Issue number	2
DOIs	https://doi.org/10.1159/000228337
Publication status	Published - 2009

Research programs

EMC MM-02-72-01
EMC MM-03-61-05-A

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000228337

http://hdl.handle.net/1765/24929

Cite this

@article{fda34e7b22944c63b34db0f2fa23f59e,

title = "The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa",

abstract = "Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established. Copyright (C) 2009 S. Karger AG, Basel",

author = "{van der Zee}, Hessel and {de Boer}, J and Errol Prens and GBE Jemec",

year = "2009",

doi = "10.1159/000228337",

language = "Undefined/Unknown",

volume = "219",

pages = "143--147",

journal = "Dermatology",

issn = "1018-8665",

publisher = "Karger",

number = "2",

}

TY - JOUR

T1 - The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa

AU - van der Zee, Hessel

AU - de Boer, J

AU - Prens, Errol

AU - Jemec, GBE

PY - 2009

Y1 - 2009

N2 - Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established. Copyright (C) 2009 S. Karger AG, Basel

AB - Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks. Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations. Method: A retrospective study in 34 patients. Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease. Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established. Copyright (C) 2009 S. Karger AG, Basel

U2 - 10.1159/000228337

DO - 10.1159/000228337

M3 - Article

C2 - 19590174

SN - 1018-8665

VL - 219

SP - 143

EP - 147

JO - Dermatology

JF - Dermatology

IS - 2

ER -